Ann: Investor Update, page-6

I expect revenue for the upcoming year will increase as distribution channels gain traction in Aust and Europe. I think expected timelines for FDA approval were overly optimistic anyway, but they did receive the fastrak application process they were after. CR could potentially be an option in the next 12 months but I think its equally likely j&j could attempt a takeover if trial goes well. This company is far from hopeless. Granted, the path to commercialisation feels painfully slow at the moment but these things take time.